Winch Advisory Services LLC Purchases 158 Shares of Johnson & Johnson (NYSE:JNJ)

Winch Advisory Services LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 8.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,996 shares of the company’s stock after buying an additional 158 shares during the period. Winch Advisory Services LLC’s holdings in Johnson & Johnson were worth $341,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. US Asset Management LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $30,000. Steward Financial Group LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $34,000. Jackson Wealth Management LLC boosted its holdings in Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after purchasing an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC boosted its holdings in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares during the last quarter. 67.84% of the stock is owned by institutional investors and hedge funds.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of the business’s stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.35% of the company’s stock.

Several brokerages have commented on JNJ. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Finally, Bank of America started coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They issued a “neutral” rating on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $184.57.

Johnson & Johnson stock traded up $6.04 during midday trading on Tuesday, reaching $183.70. 681,286 shares of the stock were exchanged, compared to its average volume of 7,890,662. The company’s fifty day moving average is $172.50 and its 200-day moving average is $168.01. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.12 and a current ratio of 1.35. The firm has a market cap of $483.00 billion, a PE ratio of 22.75, a PEG ratio of 2.71 and a beta of 0.72. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $184.20.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.61 by $0.06. The business had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. Johnson & Johnson’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.59 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.48 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.46%. The ex-dividend date is Monday, May 23rd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is 54.29%.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.